Turk

[Rupert Lowe MP @RupertLowe10]

Restore Britain will abolish Corporation Tax on the first £50,000 of profits for all companies - this takes 95% of all companies outside the corporation tax regime.

With profits over £50,000 we propose an immediate restoration of the 19% rate, with an aspiration to reduce this to 15% as soon as fiscal conditions allow.

In time, we will abolish the Bank Levy, Bank Surcharge, Residential Property Developer Tax, Energy Profits Levy, and Electricity Generator Levy.

We will be friendly to honest companies, not slavish to global business.

This is a costed plan, before any growth multiplier.

I have run and built so many small businesses. I understand what it takes.

This one policy will transform the landscape for British small business owners.

It will reinstate reward to go along with the inevitable risk.

It will make that risk worth it.

This is what we need to restore Britain's economic prosperity.

[Coffee House Stocks @CoffeeStocksGuy]

Avacta is a small British biotech most of FinTwit couldn't name.

AIM-listed. Spent the last two years selling off its diagnostics business - Launch Diagnostics went to Palex for £12.9m in 2025 - to go all-in as a pure-play oncology company.

1 June: ASCO data showed no severe cardiac toxicity on its lead cancer drug. Three weeks later, the FDA agreed it can skip straight to ONE pivotal trial for full approval - progression-free survival as the sole endpoint.

Salivary gland cancer is a small indication though. Whether this becomes a platform story or stays a one-drug story depends on what the next readout shows.
$AVCT

[Cumulus @Cumulus51896691]

Brick by brick Avacta are building the case for a modular small molecule platform to safely deliver and concentrate almost any drug in almost any tumour. Big claims - so need bulletproof data. Today's translational analysis and regulatory green light a critical part. #AVCT

[asininityandbeyond @asininitybeyond]

An incredible development + hugely positive that #AVCT is now willing to state it so clearly:

“Two analyses both demonstrate no relationship between the level of FAP expression & degree of tumor response.”

Boldness superseded only by an RNS titled “PLATFORM-VALIDATING DATA”!

[Marty McFly @Blueberrymgmnt]

Accelerated approval: Earlier approval based on promising surrogate data (e.g. ORR) = Confirmatory (Phase 3) trial required.

Full approval: Approval based on definitive evidence (such as PFS) = 🚨No planned confirmatory trial🚨

Partner has an open door. #AVCT

[Avacta @avacta]

Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference. https://t.co/9WALVjnRlB #AVCT

[Avacta @avacta]

Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer. https://t.co/WNyqFhel0I #AVCT

[Cumulus @Cumulus51896691]

Get the sense that Avacta investors who have been holding on through thin and thin (sic) for 5 years, in the belief that they were part of a really big step forward in cancer treatment, are not too far from vindication now. Targeted treatment for the untargetable. #avct

[Richard Hughes @hughesy0707]

In my personal view 2026 will be a defining point for #AVCT and ultimately for long term cancer patients.

Thanks to all shareholders and stakeholders for their support.

[Richard Hughes @hughesy0707]

Delighted to be appointed as chairman of #AVCT

My core priority is to ensure the value of preCISION is exploited to its fullest, for the benefit of all shareholders.

I am more than confident we have the team and the intellectual property to enable this.

[TVR5 @TVR5AVCT]

Congratulations to Richard Hughes on his appointment as Chair of #AVCT.

@TVR5AVCT looks forward to a transformative H2 under his chairmanship.

We wish Shaun Chilton all the best for the future.

[Turk @0turk_]

@bradloncar @BiotechTV @avacta 💯

[Christina Coughlin @coughlin582]

We are delighted to share the video recording of Science Day 2026 from #AVCT. Our team put so much into this day and their combined efforts shine through. We are thrilled to welcome a special guest in Part 2

#FOCUSOnTheWin
#HopeWithoutCompromise
#ThisIsTheTeam

[BBN @BigBiteNow]

This feels like a very positive development for #AVCT.

[RAH @RAH00084]

#AVCT

[Goldman V*king Sachs⚔️ @Borg74]

#AVCT sitting right at the Weekly 200MA.

“How fast?” The market has no real concept of time. This is a weekly chart, so my initial target is around 110p over the coming weeks, not days.

Patience pays, though many of you probably know that even better than I do. If price can reclaim and hold above the 200MA, I suspect the move could accelerate quickly.

[RAH @RAH00084]

Dose Doxorubicin safely for half a decade without a single serious cardiac event and you’re considered interesting.

Dose Exatecan safely whilst extending its release for 5 weeks and you’re more than interesting. You’re a threat.

#AVCT know their USP.

Feet up. Wait. Reap.

[Turk @0turk_]

@coughlin582 #AVCT

[RAH @RAH00084]

Primed. To. Run.

#AVCT

[TVR5 @TVR5AVCT]

Early next week the Q3W arm will receive their 2nd dose. The PK vitals be taken 24 hrs post 2nd dose.

On Tuesday #AVCT will host x2 poster sessions at AACR: AVA6103 & AVA6207.

Early the following week, the Q2W arm receives their 3rd dose.

The following week is Science Day.